You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
In a Phase I trial, non-small cell lung cancer patients with exon 20 insertions experienced durable responses with amivantamab.
The company will now initiate the dose escalation portion of a Phase I/II study and will enroll 90 NSCLC patients in the country.
A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.
The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.
A study evaluated data from a Phase I/II trial of Piqray combined with an aromatase inhibitor to find mechanisms of resistance hindering clinical benefit from the therapy.
The drug, Amelie, will be for the second-line treatment of EGFR T790-mutated non-small cell lung cancer.
The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.
Researchers performed single-cell RNA sequencing and demonstrated that the emerging heterogeneity in SCLC necessitates optimal combination treatment strategies at the outset.
BBT-176, a novel agent designed to inhibit EGFR with C797S mutations, will start first-in-human studies in NSCLC this year.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.